Evidence map›Paper›PMID 40680295›Full record

ArticleJournal of neuropathology and experimental neurology2025

Spatially resolved transcriptomics reveals a unique disease signature and potential biomarkers for chronic traumatic encephalopathy.

Catherine M Suter, Jennifer E Cropley, Andrew J Affleck, Maggie Lee, Karina Hammond, Brian Gloss, Michael E Buckland

Abstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine M SuterSchool of Medical Sciences, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-0694-6396
Jennifer E CropleyDepartment of Neuropathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Andrew J AffleckDepartment of Neuropathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Maggie LeeDepartment of Neuropathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Karina HammondDepartment of Neuropathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Brian GlossWestmead Research Hub, Westmead Institute for Medical Research, Westmead, NSW, Australia.
Michael E BucklandSchool of Medical Sciences, University of Sydney, Sydney, NSW, Australia.

Funding

Topographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomicsU19AG060909 · NIA · ALLEN INSTITUTE · PI Jennie Leigh Close, Michael Hawrylycz · 2020 to 2026
$83.6M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Adult Changes in Thought Study U01AG006781Adult Changes in Thought Study U19AG066567Australian Sports Brain BankNIA NIH HHS P30 AG066509NIA NIH HHS P50 AG005136NIA NIH HHS U01 AG006781NIA NIH HHS U19 AG060909NIA NIH HHS U19AG060909NIA NIH HHS U19 AG066567NIHSydney Local Health DistrictUW Alzheimer's Disease Research Center P30AG066509UW Alzheimer's Disease Research Center P50AG005136
6 · The paper itself

Abstract

Chronic traumatic encephalopathy (CTE) is a poorly understood environmental tauopathy uniquely associated with repetitive head injury. It is clinically ambiguous and at present can only be diagnosed post-mortem. There is a pressing need to understand CTE pathophysiology in order to identify targets for possible intervention and biomarkers for in-life diagnosis. However, molecular characterization of the disease is hampered by the stochastic distribution of CTE lesions. Here, we have taken advantage of Visium spatial transcriptomics to map gene expression in discrete CTE lesions and matched normal tissue from the same individuals. In doing so, we derived a common 21-gene "signature" of CTE lesions that highlights astrocytic activation, neuroinflammation, blood-brain barrier function, and extracellular matrix remodeling as key features of CTE lesions. Almost all CTE signature genes were strongly expressed in astrocytes and ontological and protein association analyses implicated extracellular matrix functions as drivers of the disease. These findings provide the first glimpse into the intricate molecular dynamics underlying CTE lesions in situ and present 21 candidate molecules for the development of in-life CTE diagnostics.

Indexed as

BrainChronic Traumatic EncephalopathyTranscriptomeAdultAgedAstrocytesBiomarkersFemaleGene Expression ProfilingHumansMaleMiddle AgedBiomarkersastrogliosisCTEspatial transcriptomicstauopathytraumatic brain injury

Identifiers

PMID40680295
PMCPMC12531484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.